Dr. Ching-Lung Cheung (張正龍)
BSc(Hons), PhD HK
- Committee Member of American Society of Bone and Mineral Research (ASBMR), United States
- Committee Member of Hong Kong Osteoporosis Society, Hong Kong
- Committee Member of Hong Kong Pharmacology Society
- Associate Editor, Osteoporosis and Sarcopenia
Dr Ching-Lung Cheung obtained his PhD in genetic epidemiology of osteoporosis at the University of Hong Kong (HKU). He received post-doctoral training in the Institue For Aging Research, Hebrew SeniorLife, Harvard Medical School under the supervisior of Prof. Doug Kiel and Dr. David Karasik; Genome Institute of Singapore, A*STAR, Singapore, and HKU. In 2013, Dr. Cheung took up his post as Research Assistant Professor at HKU. In 2013, he was appointed as honorary research fellow in the Institute of Translational Medicine, The University of Liverpool, UK, and worked with Prof. Sir Munir Pirmohamed. He is the principal investigator of a number of research projects funded by RGC and HMRF.
Honours and Awards
- Early Career Award, Research Grants Council, University Grants Committee, Hong Kong, 2016
- Research Output Prize: Faculty of Medicine, the University of Hong Kong, 2013
- New Investigator Award: 2011 Joint conference of European Calcified Tissue Society and International Bone and Mineral Society, 2011, and
- Poster and Oral Presentation Awards from:
- Plenary oral presentation award, the 4th Seoul International Congress of Endocrinology and Metabolism, Seoul, Korea (2016)
- The 21st Medical Research Conference, the University of Hong Kong (2016);
- 9th Metabolic Syndrome, Type 2 Diabetes and Atherosclerosis Congress, Kyoto, Japan (2014);
- APSAVD-EMW Young Investigator Oral Award – Winner: 9th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases and 16th Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Hong Kong (2014);
- 19th Medical Research Conference, the University of Hong Kong (2014);
- 16th Annual Scientific Meeting of Institute of Cardiovascular Science and Medicine (2012);
- 2010 Annual Meeting of the Hong Kong Society of Endocrinology, Metabolism and Reproduction (2010)
My Research Interests
- Precision medicine is an emerging form of disease prediction, diagnosis, and prevention that uses genetic, biomarkers, and other personalized information to deliver the right treatment, to the right person, at the right time. As the underyling cause of disease could be different among patients, the use of Precision Medicine should both improve patient outcomes and deliver benefits to the health service, based on patient's individualized makeup.
Development of precision medicine requires a multidisciplinary collaboration, including medicine, pharmacy, epidemiology, genetics and genomics, statistics, and computer science. Our team has a track record in the above areas and established collaboration with experts in different areas, allowing us to develop innovative precision medicine tools and enabling their impact in health management.
My research interest in precision medicine:
- 1) Musculoskeletal traits
- 2) Endocrine diseases
- 3) Prevention of adverse drug reaction
Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Chan EW, Kung AW, Wong IC, Cheung CL* (*Corresponding author) (2018) Association of Alendronate and Risk of Cardiovascular Events in Patients with Hip Fracture. Journal of Bone and Mineral Research (Accepted)
(Endocrinology & Metabolism: 2016 ISI impact factor: 6.3; Percentile: 90.2)
Moayyeri A*, Cheung CL* (*Co-first author), Tan KCB, Morris JA, Cerani A, Mohney RP, Richard JB, Hammond C, Spector TD, Menni C (2018) Metabolomic pathways to osteoporosis in middle-aged women: A genome-metabolome-wide Mendelian randomization study. Journal of Bone and Mineral Research (Accepted)
(Endocrinology & Metabolism: 2016 ISI impact factor: 6.3; Percentile: 90.2)
Cheung CL* (*Corresponding author), Sing CW, Tang CSM, Cheng VKF, Pirmohamed M, Choi CH, Hung CS, Lau E, Lee KF, Mak MW, Leung J, Wong TW, Ho AYY, Chan KW, Hung V, Tam V, Siu SC, Sham PC, Cheung BMY, Wong ICK, Tan KCB, Kung AWC. (2016) HLA-B*38:02:01 Predicts Carbimazole/Methimazole-Induced Agranulocytosis. Clinical Pharmacology and Therapeutics;99(5):555-61
(Pharmacology & Pharmacy: 2016 ISI impact factor: 7.3; Percentile: 95.5)
Cheung CL* (*Corresponding author), Lau KS, Ho AY, Lee KK, Tiu SC, Lau EY, Leung J, Tsang MW, Chan KW, Yeung CY, Woo YC, Cheung ENY, Hung VHF, Pang HK, Hung CS, Sham PC*, Kung AWC*. Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24.3. Nature Genetics;44:1026-1029
(Genetics & Heredity: 2012 ISI impact factor: 35.2; Percentile: 99.1)
- Cheung CL* (*Corresponding author), Tan KC, Kung AW. Cohort Profile: The Hong Kong Osteoporosis Study and the follow-up study. (2018) International Journal of Epidemiology. (Accepted) (Public, Environmental, and Occupational Health: 2016 ISI impact factor: 7.7; Percentile: 97.4)
- Lau WCY, Chan EW, Cheung CL, Sing CW, Man KKC, Lip GYH, Siu CW, Lam JKY, Lee ACH, Wong IC. (2017) Association between Dabigatran versus Warfarin and Risk of Osteoporotic Fractures among Patients with Nonvalvular Atrial Fibrillation. JAMA; 317(11):1151-1158 (Medicine, General & Internal: 2016 ISI impact factor: 44.4; Percentile: 98.4).
- Leung RYH, Han Y, Sing CW, Cheung BMY, Wong ICK, Tan KCB, Kung AWC, Cheung CL* (*Corresponding author). (2017) Serum 25-Hydroxyvitamin D and the risk of stroke in Hong Kong Chinese. Thrombosis and Haemostasis;117(1):158-163 (Peripheral Vascular disease: 2016 ISI impact factor: 5.6; Percentile: 91.2)
- Dalgaard K, Landgraf K, Heyne S, Lempradl A, Longinotto J, Gossens K, Ruf M, Orthofer M, Strogantsev R, Selvaraj M, Lu TTH, Casas E, Teperino R, Surani MA, Zvetkova I, Rimmington D, Tung YCL, Lam B, Larder R, Yeo GSH, O’Rahilly S, Whitelaw E, Penninger JM, Jenuwein T, Cheung CL, Ferguson-Smith AC, Coll AP, Körner A, Pospisilik JA (2016) Loss of Trim28 triggers bi-stable epigenetic obesity: Evidence for polyphenism in mouse and man. Cell; 164(3):353–364 (Biochemistry & Molecular Biology: 2016 ISI impact factor: 30.4; Percentile: 99.8)
- Cheung CL* (*Corresponding author), Lam KSL, Cheung BMY. (2016) Evaluation of cutpoints for low lean mass and slow gait speed in predicting death in the National Health and Nutrition Examination Survey 1999-2004. Journals of Gerontology series A-Biological Sciences and Medical Sciences;71(1):90-5 (Geriatrics & Gerontology: 2016 ISI impact factor: 6.0; Percentile: 96.7)
- Cheung CL* (*Corresponding author), Lam KSL, Wong ICK, Cheung BMY. (2014) Non-invasive Score Identifies Ultrasound-diagnosed Non-Alcoholic Fatty Liver Disease and Predicts Mortality in United States. BMC Medicine; 10;12:154 (Medicine, General & Internal: 2014 ISI impact factor: 7.3; Percentile: 94.5)
- Cheung CL, Tan KCB, Lam KSL, Cheung BMY. (2013) The relationship between glucose metabolism, metabolic syndrome, and bone-specific alkaline phosphatase: A structural equation modeling approach. Journal of Clinical Endocrinology and Metabolism;98(9):3856-63 (Endocrinology and Metabolism: 2013 ISI impact factor: 6.3; Percentile: 89.9)
- Cheung CL* (*Corresponding author), Lau KS, Sham PC, Tan KC, Kung AW. (2013) GREM2 is Significantly Associated with Bone Mineral Density in Southern Chinese. Journal of Clinical Endocrinology and Metabolism;98:E1557-61 (Endocrinology and Metabolism: 2013 ISI impact factor: 6.3; Percentile: 89.9)
- Cheung CL, Lam KSL, Cheung BMY. (2013) Beta-2 microglobulin is an independent predictor of all-cause and cardiovascular mortality among US adults. International Journal of Cardiology;168(5):4811-3 (Cardiac & cardiovascular systems: 2013 ISI impact factor: 6.2; Percentile: 91.6)
- Cheung CL, Livshits G, Zhou Y, Meigs JB, McAteer JB, Florez JC, Cupples LA, Demissie S, Kiel DP, Karasik D. (2010) Hip Geometry Variation Is Associated with Bone Mineralization Pathway Gene Variants: the Framingham Study. Journal of Bone and Mineral Research;25:1564-1571 (Endocrinology & Metabolism: 2010 ISI impact factor: 7.1; Percentile: 91.8)
- Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Järvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hyppönen E, Spector TD (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study, Lancet;376;180-8 (Medicine, General & Internal: 2010 ISI impact factor: 33.6; Percentile: 99)
- From 2014 to 2018 Apr: 8 grants as PI, with the total funding over HKD$10M.
- RGC (17104314): “Genetics and genomics of anti-thyroid drug induced agranulocytosis” 2014/2015 (HKD$905,558 for three years, PI)
- HMRF (12132451): “The role of Vitamin D and bone metabolism in cardiovascular events risk, an interaction or mediation? An 11 year follow-up study” 2014/2015 (HKD$999,736 for two years, PI)
- HMRF (02132726): “Pharmacogenomics Assessment of Serious Cutaneous Adverse drug reactions (PASCA)” 2014/2015 (HKD$ 910,176 for two years, PI)
- RGC/ECS (27100416): “Metabolomic Study of Osteoporosis in Southern Chinese” 2016/2017 (HKD$ 1,455,193 for four years, PI)
- NSFC/RGC joint grant (N_HKU729/16): “Identification of susceptibility genes involved in the pathogenesis and prediction of thyrotoxic periodic paralysis” 2016/2017 (HKD$956,480 for four years, PI)
- S.K. Yee Medical foundation grant (2161218): “Genetic screening service of HLA-B*38:02 in people prescribing antithyroid drug” 2016/2017 (HKD$899,708 for 2 years, PI)
- HMRF (05162796): “AKAP11 as a positive regulator of osteogenesis” 2017/2018 (HKD$1,198,862 for two years, PI)
- Beat Drug Fund (grant number NA): “A Comprehensive Program for Evaluation of Musculoskeletal Health and Pharmacist Medication Review” 2017/2018 (HKD$2,828,995.4 for three years, PI)
Seeking MPhil/PhD candidates:
The Department of Pharmacology and Pharmacy is inviting graduate students who are interested in conducting translational research in the area of "Pharmacogenomics and Precision Medicine" to join the Department. We are interested in the following research goals:
- To develop precision medicine for osteoporosis and related diseases and traits by combining lifestyle, clinical risk factors, biomarkers, and genetic/genomic risk factors. We are devoted to develop algorithms to predict disease risk, accurate diagnose, and optimize treatment for patients based on their personal, clinical, and genetic profiles.
- To avoid adverse drug reaction of commonly used medication by identification of the associated genetic marker(s). Screening of patients prior medication will help enhancing safe medication.
For further information about the project and suitability, please email Dr. Ching-Lung Cheung (email: firstname.lastname@example.org).
Current Group Members
- Miss. Chor-Wing Sing (PhD student)
- Mr. Raymond Leung (MPhil student)
- Mr. Vincent Cheng (MPhil student)
- Miss. Yi Han (MMedSc student)
- Miss. Alison Siu (Research nurse)
- Miss. Grace Lee (Research assistant)
- Miss. Flora Law (Laboratory assistant)
- Miss. Winnie Kong (Laboratory assistant)
- Mr. Andy Ho (Research assistant)
- Mr. Jeremy Lo (Research assistant)
- Mr. Jimmy Law (Student research assistant)
1/F, The Hong Kong Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road, Pokfulam, Hong Kong SAR, China.